ZW220, a NaPi2b-directed TOPO1i ADC, demonstrates compelling preclinical activity in NSCLC, ovarian and uterine cancer models, with a favorable toxicology profile in NHPs
ZW220, a NaPi2b-directed TOPO1i ADC, demonstrates compelling preclinical activity in NSCLC, ovarian and uterine cancer models, with a favorable toxicology profile in NHPs
Beyond ADC Target Expression: Understanding ADC Properties and Pharmacology
Beyond ADC Target Expression: Understanding ADC Properties and Pharmacology
ZW251, a novel glypican-3-targeting antibody-drug conjugate bearing a topoisomerase I inhibitor payload, demonstrates compelling preclinical activity in hepatocellular carcinoma models
ZW251, a novel glypican-3-targeting antibody-drug conjugate bearing a topoisomerase I inhibitor payload, demonstrates compelling preclinical activity in hepatocellular carcinoma models
Phase 1 Study of Zanidatamab Zovodotin (ZW49): Safety Profile and Recommended Dose (RD) in Patients with Human Epidermal Growth Factor 2 (HER2)-positive Solid Cancers
Phase 1 Study of Zanidatamab Zovodotin (ZW49): Safety Profile and Recommended Dose (RD) in Patients with Human Epidermal Growth Factor 2 (HER2)-positive Solid Cancers
Refining our understanding of ADCs: Drug development insights from 40 years of data
Refining our understanding of ADCs: Drug development insights from 40 years of data
